Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous
Dan-Dan Xiong1, Yue Qin2, Wen-Qing Xu1
1Department of Pathology, First Affiliated Hospital of Guangxi Medical University, No. 6. Shuangyong Rd, Nanning, 530021, Guangxi, China.
Background And Objectives:
Pharmacological control against ovarian serous cystadenocarcinoma has received increasing attention. The purpose of this study was to investigate multi-drug treatments as synergetic therapy for ovarian serous cystadenocarcinoma and to explore their mechanisms of action by the network pharmacology method.
Methods:
Genes acting on ovarian serous cystadenocarcinoma were first collected from GEPIA and DisGeNET. Gene Ontology annotation, Kyoto Encyclopedia of Genes and Genomes pathway, Reactome pathway, and Disease Ontology analyses were then conducted. A connectivity map analysis was employed to identify compounds as treatment options for ovarian serous cystadenocarcinoma. Targets of these compounds were obtained from the Search Tool for Interacting Chemicals (STITCH). The intersections between the ovarian serous cystadenocarcinoma-related genes and the compound targets were identified. Finally, the Kyoto Encyclopedia of Genes and Genomes and Reactome pathways in which the overlapped genes participated were selected, and a correspondence compound-target pathway network was constructed.
Results:
A total of 541 ovarian serous cystadenocarcinoma-related genes were identified. The functional enrichment and pathway analyses indicated that these genes were associated with critical tumor-related pathways. Based on the connectivity map analysis, five compounds (resveratrol, MG-132, puromycin, 15-delta prostaglandin J2, and valproic acid) were determined as treatment agents for ovarian serous cystadenocarcinoma. Next, 48 targets of the five compounds were collected. Following mapping of the 48 targets to the 541 ovarian serous cystadenocarcinoma-related genes, we identified six targets (PTGS1, FOS, HMOX1, CASP9, PPARG, and ABCB1) as therapeutic targets for ovarian serous cystadenocarcinoma by the five compounds. By analysis of the compound-target pathway network, we found the synergistic anti-ovarian serous cystadenocarcinoma potential and the underlying mechanisms of action of the five compounds.
Conclusion:
In summary, latent drugs against ovarian serous cystadenocarcinoma were acquired and their target actions and pathways were determined by the network pharmacology strategy, which provides a new prospect for medicamentous therapy for ovarian serous cystadenocarcinoma. However, further in-depth studies are indispensable to increase the validity of this study.
Insights
Network pharmacology identified five compounds, including resveratrol and valproic acid, as potential synergistic treatments for ovarian serous cystadenocarcinoma. This study reveals key therapeutic targets and pathways for drug development against this cancer.
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Ovarian serous cystadenocarcinoma treatment is an area of growing research interest.
- Pharmacological interventions are being explored for their therapeutic potential.
Purpose of the Study:
- To investigate multi-drug treatments for synergistic effects in ovarian serous cystadenocarcinoma.
- To elucidate the mechanisms of action for these multi-drug therapies using network pharmacology.
Main Methods:
- Collected ovarian serous cystadenocarcinoma-related genes from GEPIA and DisGeNET.
- Performed Gene Ontology, KEGG, Reactome, and Disease Ontology analyses.
- Utilized connectivity map analysis to identify potential treatment compounds and their targets via STITCH, constructing a compound-target-pathway network.
Main Results:
- Identified 541 ovarian serous cystadenocarcinoma-related genes associated with critical tumor pathways.
- Determined five compounds (resveratrol, MG-132, puromycin, 15-delta prostaglandin J2, valproic acid) as potential agents.
- Identified six key therapeutic targets (PTGS1, FOS, HMOX1, CASP9, PPARG, ABCB1) and elucidated synergistic anti-cancer mechanisms.
Conclusions:
- Network pharmacology identified potential drugs and their mechanisms for ovarian serous cystadenocarcinoma.
- This approach offers new prospects for drug-based therapy development.
- Further validation studies are necessary to confirm these findings.
More Related Videos
22:10Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
08:28Assessment of the Effects of Endocrine Disrupting Compounds on the Development of Vertebrate Neural Network Function Using Multi-electrode Arrays
Published on: April 26, 2018
Related Concept Videos
Multi-input and Multi-variable systems
In the absence of...
Multi-Step Reactions
Multi-species Conserved Sequences
Although the genome of each species varies greatly from each other, a few sequences are highly conserved. Such conserved...
Insertion of Multi-pass Transmembrane Proteins in the RER
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
Multi-pass Transmembrane Proteins and β-barrels
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...